{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T10:29:04Z","timestamp":1746786544206},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00108-019-00700-3","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T09:03:03Z","timestamp":1572858183000},"page":"1311-1318","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Angeborene St\u00f6rungen des High-density-Lipoprotein-Stoffwechsels"],"prefix":"10.1007","volume":"60","author":[{"given":"Arnold","family":"von Eckardstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00392-017-1106-1","volume":"106","author":"W M\u00e4rz","year":"2017","unstructured":"M\u00e4rz\u00a0W, Kleber\u00a0ME, Scharnagl\u00a0H, Speer\u00a0T et\u00a0al (2017) HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol 106:663\u2013675","journal-title":"Clin Res Cardiol"},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.2215\/CJN.00730116","volume":"11","author":"B Bowe","year":"2016","unstructured":"Bowe\u00a0B, Xie\u00a0Y, Xian\u00a0H, Balasubramanian\u00a0S, Zayed\u00a0MA, Al-Aly\u00a0Z (2016) High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans. Clin J Am Soc Nephrol 11:1784\u20131793","journal-title":"Clin J Am Soc Nephrol"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","volume":"68","author":"DT Ko","year":"2016","unstructured":"Ko\u00a0DT, Alter\u00a0DA, Guo\u00a0H et al (2016) High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART Study. J\u00a0Am Coll Cardiol 68:2073\u20132083","journal-title":"J Am Coll Cardiol"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen\u00a0CM, Varbo\u00a0A, Nordestgaard\u00a0BG (2017) Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart\u00a0J 38:2478\u20132486","journal-title":"Eur Heart J"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1253\/circj.CJ-13-1025","volume":"77","author":"W Annema","year":"2013","unstructured":"Annema\u00a0W, von Eckardstein\u00a0A (2013) High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ\u00a0J 77:2432\u20132448","journal-title":"Circ J"},{"key":"700_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight\u00a0BF, Peloso\u00a0GM, Orho-Melander\u00a0M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a\u00a0mendelian randomisation study. Lancet 380:572\u2013580","journal-title":"Lancet"},{"key":"700_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30264-5","author":"RA Hegele","year":"2019","unstructured":"Hegele\u00a0RA, Bor\u00e9n\u00a0J, Ginsberg\u00a0HN et\u00a0al (2019) Rare dyslipidaemias: from phenotype to genotype to management. A European Atherosclerosis Society Task Force consensus statement. Lancet Diabetes Endocrinol. \nhttps:\/\/doi.org\/10.1016\/S2213-8587(19)30264-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"700_CR8","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1194\/jlr.M088203","volume":"59","author":"AS Geller","year":"2018","unstructured":"Geller\u00a0AS, Polisecki\u00a0EY, Diffenderfer\u00a0MR et\u00a0al (2018) Genetic and secondary causes of severe HDL deficiency and cardiovascular disease. J\u00a0Lipid Res 59:2421\u20132435","journal-title":"J Lipid Res"},{"issue":"4","key":"700_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jacl.2008.06.002","volume":"2","author":"RD Santos","year":"2008","unstructured":"Santos RD, Asztalos BF, Martinez LR, Miname MH, Polisecki E, Schaefer EJ (2008) Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states. J Clin Lipidol 2(4):237\u2013247. \nhttps:\/\/doi.org\/10.1016\/j.jacl.2008.06.002","journal-title":"J Clin Lipidol"},{"issue":"12","key":"700_CR10","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1161\/01.ATV.14.12.1915","volume":"14","author":"R R\u00f6mling","year":"1994","unstructured":"R\u00f6mling\u00a0R, von Eckardstein\u00a0A, Funke\u00a0H, Motti\u00a0C, Fragiacomo\u00a0GC, Noseda\u00a0G, Assmann\u00a0G (1994) A\u00a0nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasmas. Arterioscler Thromb 14(12):1915\u20131922","journal-title":"Arterioscler Thromb"},{"issue":"7","key":"700_CR11","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1161\/01.CIR.94.7.1622","volume":"94","author":"R Miccoli","year":"1996","unstructured":"Miccoli\u00a0R, Bertolotto\u00a0A, Navalesi\u00a0R, Odoguardi\u00a0L, Boni\u00a0A, Wessling\u00a0J, Funke\u00a0H, Wiebusch\u00a0H, Eckardstein\u00a0A, Assmann\u00a0G (1996) Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I(L141R)Pisa, and an apolipoprotein A-I null allele in patients with absence of HDL cholesterol, corneal opacifications, and coronary heart disease. Circulation 94(7):1622\u20131628","journal-title":"Circulation"},{"key":"700_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pcad.2016.08.006","volume":"59","author":"EJ Schaefer","year":"2016","unstructured":"Schaefer\u00a0EJ, Anthanont\u00a0P, Diffenderfer\u00a0MR, Polisecki\u00a0E, Asztalos\u00a0BF (2016) Diagnosis and treatment of high density lipoprotein deficiency. Prog Cardiovasc Dis 59:97\u2013106","journal-title":"Prog Cardiovasc Dis"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"e8148","DOI":"10.1097\/MD.0000000000008148","volume":"96","author":"C Lu","year":"2017","unstructured":"Lu\u00a0C, Zuo\u00a0K, Lu\u00a0Y et al (2017) Apolipoprotein A\u20111-related amyloidosis 2 case reports and review of the literature. Medicine 96:e8148","journal-title":"Medicine"},{"key":"700_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jmb.2015.10.029","volume":"428","author":"M Das","year":"2016","unstructured":"Das\u00a0M, Wilson\u00a0CJ, Mei\u00a0X, Wales\u00a0TE, Engen\u00a0JR, Gursky\u00a0O (2016) Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A\u2011I: What makes the protein amyloidogenic? J\u00a0Mol Biol 428:449\u2013462","journal-title":"J Mol Biol"},{"key":"700_CR15","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","volume":"299","author":"R Frikke-Schmidt","year":"2008","unstructured":"Frikke-Schmidt\u00a0R, Nordestgaard\u00a0BG, Stene\u00a0MC et al (2008) Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299:2524\u20132532","journal-title":"JAMA"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.5551\/jat.43257","volume":"25","author":"J Muratsu","year":"2018","unstructured":"Muratsu\u00a0J, Koseki\u00a0M, Masuda\u00a0D et\u00a0al (2018) Accelerated atherogenicity in Tangier Disease. J\u00a0Atheroscler Thromb 25:1076\u20131085","journal-title":"J Atheroscler Thromb"},{"key":"700_CR17","first-page":"2937","volume-title":"The metabolic and molecular bases of inherited disease","author":"G Assmann","year":"2001","unstructured":"Assmann\u00a0G, von Eckardstein\u00a0A, Brewer\u00a0HB Jr (2001) Tangier Disease. In: Scriver\u00a0CR, Beaudet\u00a0AL, Sly\u00a0ES, Valle\u00a0D (Hrsg) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, S 2937\u20132960"},{"key":"700_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clinbiochem.2014.08.014","volume":"48","author":"R Saeedi","year":"2015","unstructured":"Saeedi\u00a0R, Li\u00a0M, Frohlich\u00a0J (2015) A review on lecithin:cholesterol acyltransferase deficiency. Clin Biochem 48:472\u2013475","journal-title":"Clin Biochem"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.numecd.2018.09.006","volume":"29","author":"R Fellin","year":"2019","unstructured":"Fellin\u00a0R, Manzato\u00a0E (2019) Lipoprotein\u2011X fifty years after its original discovery. Nutr Metab Cardiovasc Dis 29:4\u20138","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"e0150083","DOI":"10.1371\/journal.pone.0150083","volume":"11","author":"A Ossoli","year":"2016","unstructured":"Ossoli\u00a0A, Neufeld\u00a0EB, Thacker\u00a0SG et\u00a0al (2016) Lipoprotein X causes renal disease in LCAT deficiency. PLoS ONE 11:e150083","journal-title":"PLoS ONE"},{"key":"700_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1161\/CIRCULATIONAHA.118.034706","volume":"138","author":"F Oldoni","year":"2018","unstructured":"Oldoni\u00a0F, Baldassarre\u00a0D, Castelnuovo\u00a0S et\u00a0al (2018) Complete and partial LCAT deficiency are differentially associated with atherosclerosis. Circulation 138:1000\u20131007","journal-title":"Circulation"},{"key":"700_CR22","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","volume":"125","author":"RS Rosenson","year":"2012","unstructured":"Rosenson\u00a0RS, Brewer\u00a0HB Jr, Davidson\u00a0WS et\u00a0al (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:1905\u20131919","journal-title":"Circulation"},{"key":"700_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.5414\/CNP69213","volume":"69","author":"P Aranda","year":"2008","unstructured":"Aranda\u00a0P, Valdivielso\u00a0P, Pisciotta\u00a0L et al (2008) Therapeutic management of a\u00a0new case of LCAT deficiency with a\u00a0multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). Clin Nephrol 69:213\u2013218","journal-title":"Clin Nephrol"},{"key":"700_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1194\/jlr.M055665","volume":"56","author":"RS Kootte","year":"2015","unstructured":"Kootte\u00a0RS, Smits\u00a0LP, van der Valk\u00a0FM et al (2015) Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J\u00a0Lipid Res 56:703\u2013712","journal-title":"J Lipid Res"},{"key":"700_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1161\/CIRCRESAHA.115.306223","volume":"118","author":"RD Shamburek","year":"2016","unstructured":"Shamburek\u00a0RD, Bakker-Arkema\u00a0R, Shamburek\u00a0AM et al (2016) Safety and tolerability of ACP-501, a\u00a0recombinant human lecithin:cholesterol acyltransferase, in a\u00a0Phase 1 single-dose escalation study. Circ Res 118:73\u201382","journal-title":"Circ Res"},{"key":"700_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams\u00a0D, Koike\u00a0H, Slama\u00a0M, Coelho\u00a0T (2019) Hereditary transthyretin amyloidosis: a\u00a0model of medical progress for a\u00a0fatal disease. Nat Rev Neurol 15:387\u2013404","journal-title":"Nat Rev Neurol"},{"key":"700_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall\u00a0AR, Rader\u00a0DJ (2018) Trials and tribulations of CETP Inhibitors. Circ Res 122:106\u2013112","journal-title":"Circ Res"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1161\/ATVBAHA.117.309284","volume":"37","author":"S Velagapudi","year":"2017","unstructured":"Velagapudi\u00a0S, Yalcinkaya\u00a0M, Piemontese\u00a0A et al (2017) VEGF\u2011A regulates cellular localization of SR-BI as well as transendothelial transport of HDL but not LDL. Arterioscler Thromb Vasc Biol 37:794\u2013803","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7757","key":"700_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1140-4","volume":"569","author":"L Huang","year":"2019","unstructured":"Huang\u00a0L, Chambliss\u00a0KL, Gao\u00a0X et al (2019) SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. Nature 569(7757):565\u2013569","journal-title":"Nature"},{"key":"700_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1056\/NEJMoa0907687","volume":"364","author":"M Vergeer","year":"2011","unstructured":"Vergeer\u00a0M, Korporaal\u00a0SJ, Franssen\u00a0R et\u00a0al (2011) Genetic variant of the scavenger receptor BI in humans. N\u00a0Engl J Med 364:136\u2013145","journal-title":"N Engl J Med"},{"key":"700_CR31","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni\u00a0P, Khetarpal\u00a0SA, Larach\u00a0DB et\u00a0al (2016) Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351:1166\u20131171","journal-title":"Science"},{"key":"700_CR32","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/01.ATV.13.5.720","volume":"13","author":"RA Hegele","year":"1993","unstructured":"Hegele\u00a0RA, Little\u00a0JA, Vezina\u00a0C et\u00a0al (1993) Hepatic lipase deficiency. Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 13:720\u2013728","journal-title":"Arterioscler. Thromb."},{"key":"700_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.atherosclerosis.2018.12.024","volume":"282","author":"G Silbernagel","year":"2019","unstructured":"Silbernagel\u00a0G, Scharnagl\u00a0H, Kleber\u00a0ME et\u00a0al (2019) LDL triglycerides, hepatic lipase activity, and coronary artery disease: an epidemiologic and Mendelian randomization study. Atherosclerosis 282:37\u201344","journal-title":"Atherosclerosis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-00700-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:10:42Z","timestamp":1604362242000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-00700-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,4]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-00700-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,4]]},"assertion":[{"value":"4 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0von Eckardstein gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}